Cytori Therapeutics Inc

Find Ratings Reports
CYTX : NASDAQ : Health Care
$2.03 | %
Today's Range: 2.03 - 2.09
Avg. Daily Volume: 207,000
07/22/16 - 4:00 PM ET

Financial Analysis


CYTORI THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2016 has increased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. CYTORI THERAPEUTICS INC has average liquidity. Currently, the Quick Ratio is 1.05 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 133.38% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY16 Q1 FY15
Net Sales ($mil)2.922.35
EBITDA ($mil)-4.81-5.34
EBIT ($mil)-5.1-5.55
Net Income ($mil)-5.34-21.96


Balance Sheet Q1 FY16 Q1 FY15
Cash & Equiv. ($mil)9.3613.2
Total Assets ($mil)32.9237.05
Total Debt ($mil)16.9225.68
Equity ($mil)7.74-23.2


Profitability Q1 FY16 Q1 FY15
Gross Profit Margin90.5483.59
EBITDA Margin-164.7-227.62
Operating Margin-174.67-236.7
Sales Turnover0.370.23
Return on Assets-6.45-132.06
Return on Equity-27.440.0
Debt Q1 FY16 Q1 FY15
Current Ratio1.711.06
Debt/Capital0.6910.35
Interest Expense0.661.07
Interest Coverage-7.76-5.18


Share Data Q1 FY16 Q1 FY15
Shares outstanding (mil)13.317.61
Div / share0.00.0
EPS-0.45-3.15
Book value / share0.58-3.05
Institutional Own % n/a n/a
Avg Daily Volume1124059.01473822.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.37 indicates a premium versus the S&P 500 average of 2.80 and a significant discount versus the industry average of 10.73. The price-to-sales ratio is above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CYTORI THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CYTX NM Peers 38.57   CYTX NM Peers 20.77

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CYTX's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CYTX's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CYTX NA Peers 111.79   CYTX NA Peers 1.06

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CYTX 3.37 Peers 10.73   CYTX 98.22 Peers -16.43

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CYTX is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CYTX is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CYTX 2.13 Peers 370.84   CYTX 43.72 Peers 40.78

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CYTX is trading at a significant discount to its industry on this measurement.

 

Average. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

CYTX is keeping pace with its peers on the basis of sales growth.

 

 

Latest Stock Upgrades/Downgrades